Cefuroxime

J01D - Other beta-lactam antibacterials ATC J01DC02 Small molecule approved 1983 Parenteral Natural product

🧬 Cross-allergy: Cephalosporins

JFDA label: Zinoxime IV/IM

Mechanism of Action

Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.

Indications

Approved

Acute bacterial exacerbations of chronic bronchitis (tablets only)
Acute bacterial maxillary sinusitis (tablets and oral suspension only)
Acute otitis media (tablets and oral suspension only)
Bone and joint infections (injection only)
Lower respiratory tract infections (injection only)
Lyme disease (early) (tablets only)
Pharyngitis/tonsillitis (tablets and oral suspension only)
Septicemia (injection only)
Skin and skin structure infection (impetigo) (oral suspension only)
Skin and skin structure infection (injection; tablets [uncomplicated infections only])
Surgical (perioperative) prophylaxis (injection only)
Urinary tract infections (tablets and injection only)

Off-label

Bite wounds (animal)
Intra-abdominal Infections

Antimicrobial Spectrum

Expected / intrinsic spectrum (EUCAST breakpoints & labels) — not local resistance. Source: EUCAST v16 · curated · openfda-label.

Bacteria

Organism	Activity	MIC
Borrelia burgdorferi	Active	—
Escherichia coli	Susceptible	8.0 mg/L
Haemophilus influenzae	Susceptible	4.0 mg/L
Haemophilus influenzae	Susceptible	1.0 mg/L
Haemophilus parainfluenzae	Active	—
Klebsiella pneumoniae	Active	—
Moraxella catarrhalis	Susceptible	4.0 mg/L
Morganella morganii	Active	—
Neisseria gonorrhoeae	Active	—
Proteus inconstans	Active	—
Proteus mirabilis	Active	—
Providencia rettgeri	Active	—
Staphylococcus aureus	Susceptible	1.0 mg/L
Staphylococcus epidermidis	Active	—
Staphylococcus saprophyticus	Active	—
Streptococcus agalactiae	Active	—
Streptococcus pneumoniae	Susceptible	0.125 mg/L
Streptococcus pneumoniae	Susceptible	0.5 mg/L
Streptococcus pyogenes	Active	—
Viridans group streptococci	Susceptible	0.5 mg/L
Escherichia coli	Resistant	8.0 mg/L

Class profile

gramStatus	Both
spectrumBreadth	Moderate
atypicalCoverage	No
isBactericidal	1
moaCategory	Cell wall synthesis inhibitor (beta-lactam, 2nd generation cephalosporin)
pdIndex	Time-dependent
postAntibioticEffect	None
mrsaCoverage	0
resistanceMechanisms	Beta-lactamase production,PBP mutations

Contraindications

Source: Lexicomp

Hypersensitivity to cefuroxime, any component of the formulation, or other beta-lactam antibacterial drugs (eg, penicillins and cephalosporins) Absolute

Adverse Reactions

Very Common >10%Common 1–10%Uncommon 0.1–1% Rare 0.01–0.1%Very Rare <0.01%Not Known

Cardiac disorders (1)

Common Local thrombophlebitis

Vascular disorders (1)

Common Thrombophlebitis (IV)

Hepatobiliary disorders (3)

Common increased serum alkaline phosphatase · Increased serum transaminases

Uncommon Elevated liver enzymes

Renal and urinary disorders (1)

Common Vaginitis

Blood and lymphatic system disorders (3)

Common Decreased hematocrit · decreased hemoglobin · eosinophilia

Immune system disorders (3)

Common Jarisch-Herxheimer reaction

Uncommon Allergic reaction (cross-reactivity with penicillin ~1–2%) · Hypersensitivity / rash

Metabolism and nutrition disorders (1)

Common Increased lactate dehydrogenase

Gastrointestinal disorders (4)

Common Diarrhoea · Nausea · Nausea and vomiting · unpleasant taste

Skin and subcutaneous tissue disorders (1)

Common Diaper rash

Infections and infestations (1)

Uncommon Clostridioides difficile colitis

Other (1)

Very Common Gastrointestinal: Diarrhea

Dosing

Source: Lexicomp

Note: Cefuroxime axetil film-coated tablets and oral suspension are not bioequivalent and are not substitutable on a mg/mg basis. All oral doses listed are for tablet formulation: Acute bacterial maxillary sinusitis: Oral: 250 mg twice daily for 10 days Bone and joint infections: IM, IV: 1.5 g every 8 hours (adjunctive surgical intervention may be necessary); upon completion of parenteral therapy follow with oral antibiotic therapy if indicated. Acute bacterial exacerbations of chronic bronchitis: Oral: 250 to 500 mg every 12 hours for 10 days IV: 500 to 750 mg every 8 hours (complete therapy with oral dosing) Cholecystitis, mild to moderate (off-label): IV: 1.5 g every 8 hours for 4 to 7 days (provided source controlled) (IDSA [Solomkin 2010]) Intra-abdominal infection, complicated, community-acquired, mild to moderate (in combination with metronidazole): (off-label): IV: 1.5 g every 8 hours for 4 to 7 days (provided source controlled) (IDSA [Solomkin 2010]) Lyme disease (early): Oral: 500 mg twice daily for 20 days Pharyngitis/tonsillitis: Oral: 250 mg twice daily for 10 days Pneumonia, community-acquired: Note: Cefuroxime is considered an alternate therapy for CAP in adults caused by Streptococcus pneumoniae (with MICs Oral (off-label route in US): 500 mg twice daily for a minimum of 5 days (patients should be afebrile for ≥48 hours and clinically stable before discontinuing therapy) (IDSA [Mandell 2007]) IM, IV: Manufacturer's labeling: IM, IV: 750 mg every 8 hours Alternate dosing: IV: 1.5 g every 8 hours. Note: This higher dose should be considered in hospitalized patients, especially if bacteremic (Caballero-Granado 1996) Severe or complicated infections: IV: 1.5 g every 8 hours (up to 1.5 g every 6 hours in life-threatening infections) Skin/skin structure infection, uncomplicated: Oral: 250 to 500 mg every 12 hours for 10 days IM, IV: 750 mg every 8 hours Surgical (perioperative) prophylaxis: IV: Manufacturer's labeling: 1.5 g 30 minutes to 1 hour prior to procedure (if procedure is prolonged can give 750 mg every 8 hours IV or IM) Open heart: IV: 1.5 g every 12 hours for a total of 4 doses starting at anesthesia induction Alternative recommendation: 1.5 g within 60 minutes prior to surgical incision. Doses may be repeated in 4 hours if procedure is lengthy or if there is excessive blood loss (Bratzler 2013). Urinary tract infection, uncomplicated: Oral: 250 mg twice daily for 7 to 10 days IV, IM: 750 mg every 8 hours Bite wounds (animal) (off-label use) (IDSA [Stevens 2014]): Oral: 500 mg twice daily in combination with clindamycin or metronidazole for anaerobic coverage

(For additional information see "Cefuroxime: Pediatric drug information") Note: Cefuroxime axetil film-coated tablets and oral suspension are not bioequivalent and are not substitutable on a mg/mg basis. Children ≥1 year: Surgical (perioperative) prophylaxis: IV: 50 mg/kg within 60 minutes prior to surgical incision (maximum dose: 1,500 mg). Doses may be repeated in 4 hours if procedure is lengthy or if there is excessive blood loss (Bratzler 2013). Infants ≥3 months and Children: Acute bacterial maxillary sinusitis, acute otitis media: Oral: Suspension: 30 mg/kg/day in 2 divided doses for 10 days (maximum dose: 1,000 mg/day); tablet: 250 mg twice daily for 10 days IM, IV: 75 to 150 mg/kg/day divided every 8 hours (maximum dose: 6 g/day) Bone and joint infection: IM, IV: 50 mg/kg/dose every 8 hours; maximum single dose: 1,500 mg. Upon completion of parenteral therapy follow with oral antibiotic therapy if indicated. Pharyngitis/tonsillitis: Oral: Suspension: 20 mg/kg/day (maximum: 500 mg/day) in 2 divided doses for 10 days IM, IV: 75 to 150 mg/kg day divided every 8 hours (maximum: 6 g/day) Skin and skin structure infection (impetigo): Oral: Suspension: 30 mg/kg/day in 2 divided doses for 10 days (maximum dose: 1,000 mg/day) Urinary tract infection, uncomplicated (off-label dosing): Infants and Children ≥2 months to 2 years: Oral: 20 to 30 mg/kg/day divided twice daily for 7 to 14 days (AAP 2011) Children ≥2 years: Moderate to severe disease (possible pyelonephritis): Oral: 20 to 30 mg/kg/day divided twice daily (maximum dose: 1,000 mg/day) (Bradley 2012; Red Book [AAP 2012]) Adolescents: Acute bacterial exacerbations of chronic bronchitis: Oral: 250 to 500 mg every 12 hours for 10 days. Acute bacterial maxillary sinusitis: Oral: 250 mg twice daily for 10 days. Bone and joint infection: IM, IV: Refer to adult dosing. Lyme disease (early): Oral: 500 mg twice daily for 20 days. Pharyngitis/tonsillitis: Oral: 250 mg every 12 hours for 10 days. Skin/skin structure infection, uncomplicated: Oral: 250 to 500 mg every 12 hours for 10 days. Urinary tract infection, uncomplicated: Oral: 250 mg twice daily for 7 to 10 days.

Refer to adult dosing.

Oral: Manufacturer’s labeling: Adults: CrCl ≥30 mL/minute: No dosage adjustment necessary. CrCl 10 to CrCl ESRD requiring intermittent hemodialysis (IHD): Additional recommended dose based on indication should be given at the end of each dialysis session. Pediatric: There are no dosage adjustments provided in the manufacturer’s labeling; however, the following adjustments have been reported in the literature (Aronoff 2007): Note: Renally adjusted dose recommendations are based on doses of 30 mg/kg/day divided every 12 hours: CrCl ≥30 mL/minute/1.73 m2: No dosage adjustment necessary. CrCl 10 to 29 mL/minute/1.73 m2: 15 mg/kg/dose every 12 hours. CrCl 2: 15 mg/kg/dose every 24 hours. Hemodialysis: Dialyzable: 15 mg/kg/dose every 24 hours Peritoneal dialysis: 15 mg/kg/dose every 24 hours IV: Manufacturer’s labeling: Adults: CrCl >20 mL/minute: No dosage adjustment necessary. CrCl 10 to 20 mL/minute: Administer recommended dose based on indication every 12 hours CrCl Hemodialysis: Administer additional recommended dose based on indication at the end of dialysis Infants >3 months, Children, and Adolescents: Administer recommended dose based on indication but decrease frequency similar to the adult recommendations. Alternate dosing (Aronoff 2007): Peritoneal dialysis: Adults: Administer full dose every 24 hours Children: 25 to 50 mg/kg dose every 24 hours Continuous renal replacement therapy (CRRT): Adults: 1 g every 12 hours Children: 25 to 50 mg/kg every 8 hours

There are no dosage adjustments provided in the manufacturer’s labeling.

Warnings & Precautions

Source: Lexicomp

Elevated INR

May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.

Hypersensitivity reactions

Serious and occasionally severe or fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam drugs. Before initiating therapy, carefully investigate previous penicillin, cephalosporin, or other allergen hypersensitivity. Use caution if given to a patient with a penicillin or other beta-lactam allergy because cross sensitivity among beta-lactam antibacterial drugs has been established. If an allergic reaction occurs, discontinue and institute appropriate therapy.

Superinfection

Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment. Disease-related concerns:

Gastrointestinal disease

Use with caution in patients with a history of colitis.

Renal impairment

Use with caution in patients with renal impairment; modify dosage in severe impairment.

Seizure disorders

Use with caution in patients with a history of seizure disorder; cephalosporins have been associated with seizure activity, particularly in patients with renal impairment not receiving dose adjustments. Discontinue if seizures occur. Concurrent drug therapy issues:

Drug-drug interactions

Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Dosage form specific issues:

Benzyl alcohol and derivatives

Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.

Phenylalanine

Some products may contain phenylalanine.

Suspension/tablet bioequivalence

Tablets and oral suspension are not bioequivalent; do not substitute on a mg-per-mg basis.

Tablets

Should not be crushed or chewed due to a strong, persistent bitter taste. Patients unable to swallow whole tablets should be prescribed the oral suspension.

Pregnancy & Lactation

Pregnancy

FDA category B Teratogenic

Adverse events were not observed in animal reproduction studies. Cefuroxime crosses the placenta and reaches the cord serum and amniotic fluid. Placental transfer is decreased in the presence of oligohydramnios. Several studies have failed to identify an increased teratogenic risk to the fetus following maternal cefuroxime use. During pregnancy, mean plasma concentrations of cefuroxime are 50% lower, the AUC is 25% lower, and the plasma half-life is shorter than nonpregnant values. At term, plasma half-life is similar to nonpregnant values and peak maternal concentrations after IM administration are slightly decreased. Pregnancy does not alter the volume of distribution. Cefuroxime is one of the antibiotics recommended for prophylactic use prior to cesarean delivery.

Lactation

Cefuroxime is excreted in breast milk. Manufacturer recommendations vary; caution is recommended if cefuroxime IV is given to a nursing woman and it is recommended to consider discontinuing nursing temporarily during treatment following oral cefuroxime. Nondose-related effects could include modification of bowel flora.

Monitoring

Efficacy	Culture and susceptibility testing; clinical resolution (temperature, WBC, CRP, procalcitonin)
Toxicity	Renal function (dose adjustment in renal impairment); hepatic function for hepatically cleared agents; signs of C. difficile infection (diarrhoea)
Clinical pearl	Culture results guide de-escalation to narrower-spectrum therapy. Review antibiotic appropriateness at 48–72 h (antimicrobial stewardship).
Counseling	Complete the full course. Report persistent diarrhoea, rash, or lack of improvement after 48–72 h.

Chemistry & Properties

Formula	C16H16N4O8S
Molecular weight	424.39 g/mol
IUPAC name	(6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CAS	55268-75-2
PubChem CID	5479529
InChIKey	`JFPVXVDWJQMJEE-IZRZKJBUSA-N`
logP	-0.54 (XLogP -0.2)
Polar surface area	173.76 Å²
H-bond acceptors / donors	9 / 3
Drug-likeness (QED)	0.30
Lipinski violations	0

SMILES

CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@H]12)c1ccco1

Biology & Pharmacokinetics

Pharmacokinetics

BBB penetrant	Yes

Enzyme interactions

Enzyme	Role	Detail
CYP2C8	Inhibitor	—

Transporters

BCRP (Inhibitor)BSEP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)MRP2 (Inhibitor)MRP3 (Inhibitor)MRP4 (Inhibitor)OAT3 (Inhibitor)OATP1B1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)PEPT1 (Inhibitor)PEPT2 (Inhibitor)P-gp (Substrate)PEPT1 (Substrate)

Drug–drug interactions (33, DDInter)

Interacting drug	Severity	Management
Aluminum hydroxide	moderate
Amikacin	moderate
Amikacin (liposome)	moderate
Balsalazide	moderate
Calcium carbonate	moderate
Chloramphenicol	moderate
Cimetidine	moderate
Dexlansoprazole	moderate
Dicoumarol	moderate
Disulfiram	moderate
Esomeprazole	moderate
Ethinylestradiol	moderate
Famotidine	moderate
Gentamicin	moderate
Kanamycin	moderate
Lansoprazole	moderate
Magaldrate	moderate
Magnesium carbonate	moderate
Magnesium hydroxide	moderate
Magnesium oxide	moderate
Mycophenolic acid	moderate
Neomycin	moderate
Nizatidine	moderate
Omeprazole	moderate
Pantoprazole	moderate
Pemetrexed	moderate
Rabeprazole	moderate
Ranitidine	moderate
Ranitidine (bismuth citrate)	moderate
Sodium bicarbonate	moderate
Sodium citrate	moderate
Streptomycin	moderate
Warfarin	moderate

Registered Products (64)

Brand	Form / strength	Pack	Agent	Citizen (JOD)
ZILISTEN VIAL	Vial 750 mg	1 vial pack varies	Al Hilal Drug Store	1.150
Cefuzime	Powder for Injection 750 mg	1 vial	Professional Drug Store	1.210
Vaxcel Cefuroxime -	Vial 750 mg	1 vial	AL Rahma Drug Store	1.210
Zinoxime IV/IM	Vial 750 mg	One Vial	Sukhtian Group	1.210
Cefutil + Water for Injection	Injection 750 mg/ml	1 vial	pharma international	1.640
Maxil 750 Injection	Powder for Injection (as Sodium)750 mg	1 vial pack varies	Hikma Pharmaceuticals Co.Ltd/Jordan	1.640
cefutil	Vial 750 mg/ml	1 vial	Pharma International Company/ Jordan	1.640
Zinacef Inj.	Powder for Injection 750 mg	1 vial pack varies	Suleiman Tannous & Sons Co. Ltd	1.730
ZILISTEN VIAL	Vial 1.5 g	1 vial pack varies	Al Hilal Drug Store	2.040
Zinoxime IV Vial	Vial 1.5 g	One Vial	Sukhtian Group	2.230
Xorim	Vial 1500 mg	1 vial	Nabulsi Drug Store	2.370
Xorim	Vial 250 mg	5 vial	Nabulsi Drug Store	2.490
Medo-Axetine	Tablet 250 mg	10 tab	Khoury Drug Store	2.510
Cefovex	Tablet 250 mg	10 tab	Noor Drug Store	2.630
Maxil 1500 mg Sterile Powder for Injection (I.V)	Powder for Injection 1500 mg	1 vial pack varies	Hikma Pharmaceuticals Co.Ltd/Jordan	3.020
Zinacef Inj	Powder for Injection 1.5 g	1 vial	Suleiman Tannous & Sons Co. Ltd	3.180
Zinnat Susp.	Suspension 250 mg/5 ml	50 ml pack varies	Suleiman Tannous & Sons Co. Ltd	3.210
Ceftal	Tablet 250 mg	10 tab pack varies	AL-TAQADDOM PHARMACEUTICAL INDUSTRIES/JORDAN	3.350
Zinnat Susp.	Suspension 125 mg/5 ml	50 ml pack varies	Suleiman Tannous & Sons Co. Ltd	3.400
Cefurex Susp	Suspension 125 mg/5 ml	50 ml	MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN	3.410
Cefurex Suspension	Suspension 250 mg/5 ml	50 ml	MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN	3.410
Cefurex F.C Tablets	Film-Coated Tablet 125 mg	10 tab	MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN	3.430
Cefutil tab	Tablet 125 mg	10 tab	Pharma International Company/ Jordan	3.500
Xorimax	Suspension 125 mg/5 ml	70 ml	Nabulsi Drug Store	3.530
Cefurex Tablets	Tablet 250 mg	10 tab pack varies	MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN	3.560
Cefutil tab	Tablet (axetil) 250 mg	10 tab	Pharma International Company/ Jordan	3.560
Daroxime 250 TABLETS	Tablet 250 mg	10 tab pack varies	Dar Al Dawa Development and Investment Co Ltd/Jordan	3.560
Oraxim Tablets	Tablet 250 mg	10 tab	UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN	3.560
U-Cef tablet	Tablet (Axetil) 250 mg	10 tab	The Arab Pharmaceutical Manufactruing Co.	3.560
Zinnat Tablets	Tablet 250 mg	10 tab	Suleiman Tannous & Sons Co. Ltd	3.650
Zinacef Inj.	Powder for Injection 250 mg	5 vial	Suleiman Tannous & Sons Co. Ltd	3.770
Medo-Axetine	Tablet 500 mg	10 tab	Khoury Drug Store	3.920
U-cef suspension	Suspension 125 mg/5 ml	50 ml	Advanced Pharmaceutical Industry	4.000
Cefovex	Tablet 500 mg	10 tab	Noor Drug Store	4.100
Zinnat Tablets	Tablet 125 mg	10 tab	Suleiman Tannous & Sons Co. Ltd	4.440
Daroxime 250 TABLETS	Tablet 250 mg	14 tab pack varies	Dar Al Dawa Development and Investment Co Ltd/Jordan	4.980
U-Cef Tablet	Tablet ( Axetil)250 mg	14 tab	The Arab Pharmaceutical Manufactruing Co.	4.980
Ceftal	Tablet 500 mg	10 tab pack varies	AL-TAQADDOM PHARMACEUTICAL INDUSTRIES/JORDAN	5.270
Cefurex Tablets	Tablet 500 mg	10 tab pack varies	MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN	5.270
Cefutil tab	Tablet 500 mg	10 tab pack varies	Pharma International Company/ Jordan	5.270
Daroxime 500 TABLETS	Tablet 500 mg	10 tab pack varies	Dar Al Dawa Development and Investment Co Ltd/Jordan	5.270
Oraxim Tablets	Tablet 500 mg	10 tab	UNITED PHARM.MFG.CO.LTD(UPM)/JORDAN	5.270
U-Cef tablet	Tablet (Axetil) 500 mg	10 tab	The Arab Pharmaceutical Manufactruing Co.	5.270
Xorim	Vial 750 mg	5 vial	Nabulsi Drug Store	5.360
Zinoximor Tabs	Tablet 500 mg	14 tab	Sukhtian Group	5.740
Zinnat Tablet	Tablet 500 mg	10 tab	Suleiman Tannous & Sons Co. Ltd	5.860
Zinnat Susp.	Suspension 250 mg/5 ml	100 ml pack varies	Suleiman Tannous & Sons Co. Ltd	6.120
Zinnat Susp.	Suspension 125 mg/5 ml	100 ml pack varies	Suleiman Tannous & Sons Co. Ltd	6.460
Cefutil tab	Tablet 500 mg	14 tab pack varies	Pharma International Company/ Jordan	7.370
Daroxime 500 TABLETS	Tablet 500 mg	14 tab pack varies	Dar Al Dawa Development and Investment Co Ltd/Jordan	7.380
U-Cef Tablet	Tablet (Axetil)500 mg	14 tab	The Arab Pharmaceutical Manufactruing Co.	7.380
Zinacef Inj.	Powder for Injection 750 mg	5 vial pack varies	Suleiman Tannous & Sons Co. Ltd	8.010
ZILISTEN VIAL	Vial 750 mg	10 vial pack varies	Al Hilal Drug Store	10.350
Maxil 750 Injection	Powder for Injection (as Sodium)750 mg	10 vial pack varies	Hikma Pharmaceuticals Co.Ltd/Jordan	14.760
cefutil	Vial 750 mg	10 vial	Pharma International Company/ Jordan	14.760
ZILISTEN VIAL	Vial 1.5 g	10 vial pack varies	Al Hilal Drug Store	18.370
Maxil 1500 mg Sterile Powder for Injection (I.V)	Powder for Injection 1500 mg	10 vial pack varies	Hikma Pharmaceuticals Co.Ltd/Jordan	27.180
ZILISTEN VIAL	Vial 750 mg	50 vial pack varies	Al Hilal Drug Store	48.850
ZILISTEN VIAL	Vial 1.5 g	50 vial pack varies	Al Hilal Drug Store	86.800
Cefurex Tablets	Tablet 500 mg	250 tab pack varies	MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN	111.920
Cefurex Tablets	Tablet 250 mg	500 tab pack varies	MIDDLE EAST PHARMA&CHEMICAL IND/JORDAN	151.300
Cefutil tab	Tablet 250 mg	500 tab	Pharma International Company/ Jordan	151.300
Ceftal	Tablet 250 mg	1000 tab pack varies	AL-TAQADDOM PHARMACEUTICAL INDUSTRIES/JORDAN	284.750
Ceftal	Tablet 500 mg	1000 tab pack varies	AL-TAQADDOM PHARMACEUTICAL INDUSTRIES/JORDAN	447.950